Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August
Medisol Acquisition To Push Injectables Growth
Executive Summary
Lupin has pushed the launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables
You may also be interested in...
Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.
Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise
Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India